个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Efficacy and Safety of Crisugabalin (HSK16149) in Adults with Postherpetic Neuralgia: A Phase 3 Randomized Clinical Trial

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Zhang Daying[1] * ; Lei Tiechi[2] ; Qin Lanying[3] ; Li Chenyu[4] ; Lin Xuewu[5] ; Wang Huiping[6] ; Zhang Guoqiang[7] ; Zhang Shoumin[8] ; Shi Kemei[9] ; Li Linfeng[10] ; Yang Zhenling[11] ; Yang Xiumin[12] ; Ba Xiaohong[13] ; Gao Ying[14] ; Zhang Zhuobo[15] ; Wang Guonian[16] ; Wu Liming[17] ; Wang Yaping[18] ; Wang Yu[19] ; Zhu Shoumin[20] ; Shi Jihai[21] ; Ye Zhijian[22] ; Yang Chunjun[23] ; Liu Changyi[24] ; Zhang Tong[25] ; Lu Shousi[26] ; Yu Nan[27] ; Li Xiangkui[28] ; Han Xiuping[29] ; Chen Xiaoyan[30] ; Wan Li[31] ; Cheng Zhigang[32] ; Bai Nianyue[33] ; Jin Zhehu[34] ; Yu Chunshui[35] ; Zhang Weiyi[36] ; Lu Jianyun[37] ; Wang Dongmei[38] ; Sun Hui[39] ; Wu Wenzhong[40] ; Qin Pingping[41] ; Feng Zhiying[42] ; Chen Rixin[43] ; Zhang Tangde[44] ; Yang Dong[45] ; Yin Wenhao[46] ; Zhang Jianglin[47] ; Li Xin[48] ; Li Fangqiong[49] ; Wu Tingting[49] ; Lu Qianjin[50] ;
机构： [1]Department of Pain Medicine, The First Affiliated Hospital of Nanchang University, Donghu District, Nanchang, Jiangxi, China. [2]Department of Dermatology, Renmin Hospital of Wuhan University, Wuchang District, Wuhan, Hubei, China. [3]Department of Dermatology, Cangzhou People's Hospital, Cangzhou, Hebei, China. [4]Department of Neurology, Chongqing Traditional Chinese Medicine Hospital, Panxi, Jiangbei District, Chongqing, China. [5]Department of Anaesthesiology, The First Affiliated Hospital of Bengbu Medical University, Longzihu District, Bengbu, Anhui Province, China. [6]Department of Dermatovenereology, Tianjin Medical University General Hospital, Heping District, Tianjin, China. [7]Department of Dermatology, The First Hospital of Hebei Medical University, Yuhua District, Shijiazhuang, Hebei Province, China. [8]Department of Dermatology, Henan Provincial People's Hospital, Zhengzhou, Henan Province, China. [9]Pain Management Center, The Second Hospital of Tianjin Medical University, Hexi District, Tianjin, China. [10]Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Xicheng District, Beijing, China. [11]Department of Pain, The First of Affiliated Hospital of Henan University, Kaifeng, Henan, China. [12]Department of Dermatology, Beijing Tongren Hospital, Capital Medical University, Dongcheng District, Beijing, China. [13]Department of Neurology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China. [14]Department of Dermatology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Jiang'an District, Wuhan, Hubei, China. [15]Department of Neurology, The Fourth Hospital of Harbin Medical University, Nangang District, Harbin, Heilongjiang, China. [16]Department of Anesthesiology, The Fourth Hospital of Harbin Medical University, Nangang District, Harbin, Heilongjiang, China. [17]Department of Dermatology and Venereology, Affiliated Hangzhou First People's Hospital, Hangzhou, Zhejiang, China. [18]Department of Anesthesiology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China. [19]Department of Dermatology, The Affiliated Hospital of Guizhou Medical University, Yunyan District, Guiyang, Guizhou, China. [20]Department of Dermatology, People's Hospital Affiliated to Chongqing Three Gorges Medical College, Wanzhou District, Chongqing, China. [21]Department of Dermatology, The First Affiliated Hospital of Baotou Medical College, Kundulun District, Baotou, Inner Mongolia Autonomous Region, China. [22]Department of Anesthesiology, The Affiliated Jinhua Hospital of Wenzhou Medical University, Jindong District, Jinhua, Zhejiang, China. [23]Department of Dermatology and Venereology, The Second Affiliated Hospital of Anhui Medical University, Shushan District, Hefei, Anhui, China. [24]Department of Neurology, The First Hospital of Qiqihar, Longsha District, Qiqihar, Heilongjiang, China. [25]Department of Neurology, Research Ward, China Rehabilitation Research Center, Fengtai District, Beijing, China. [26]Research Ward, China Rehabilitation Research Center, Fengtai District, Beijing, China. [27]Department of Dermatology, General Hospital of Ningxia Medical University, Xingqing Area, Ningxia, Ningxia Hui Autonomous Region, China. [28]Department of Anesthesiology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Qingyang District, Chengdu, Sichuan, China. [29]Department of Dermatology, Shengjing Hospital of China Medical University, Heping District Shenyang, Liaoning, China. [30]Department of Dermatology, Xianyang Hospital of Yan'an University, Weicheng District, Xianyang, Shaanxi, China. [31]Pain Management Department, The Second Affiliated Hospital of Guangzhou Medical University, Haizhu District, Guangzhou, Guangdong, China. [32]Department of Anesthesiology, Xiangya Hospital Central South University, Changsha, Hunan, China. [33]Xiangya Hospital, Central South University, Changsha, Hunan, China. [34]Department of Dermatology, The Affiliated Hospital of Yanbian University (Yanbian Hospital), Yanji, Jilin, China. [35]Department of Dermatology, Suining Central Hospital, Chuanshan District, Suining, Sichuan, China. [36]Department of Anesthesiology, West China Hospital, Sichuan University, Wuhou District, Chengdu, Sichuan, China. [37]Department of Dermatology, The Third Xiangya Hospital of Central South University, Yuelu District, Changsha, Hunan, China. [38]Department of Chinese Medicine Dermatology, Dermatology Hospital of Southern Medical University, Yuexiu District, Guangzhou, Guangdong, China. [39]Department of Dermatology, Wuxi Second People's Hospital, Liangxi District, Wuxi, Jiangsu, China. [40]Department of Dermatology, Shenzhen Second People's Hospital, Futian District, Shenzhen, Guangdong, China. [41]Department of Dermatology, Yancheng No.1 People's Hospital, Yancheng, Hubei, China. [42]Department of Pain Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. [43]Department of Dermatology, Nanyang First People's Hospital, Nanyang, Henan, China. [44]Department of Dermatology, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China. [45]Department of Pain Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. [46]Department of Dermatology, The First Hospital of Jiaxing, Jiaxing, Zhejiang Province, China. [47]Department of Dermatology, Shenzhen People's Hospital, Luohu District, Shenzhen, Guangdong, China. [48]Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. [49]Haisco Pharmaceutical Group Co, Ltd, Wenjiang District, Chengdu, Sichuan, China. [50]Hospital for Skin Diseases (Institute of Dermatology), Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, Jiangsu, China.
出处：
DOI： 10.1001/jamadermatol.2024.3410
ISSN：

摘要：
China carries a heavy burden of postherpetic neuralgia, with an unmet need for novel drugs with greater efficacy and less prominent neurotoxic effects than existing calcium channel ligands.To investigate the efficacy and safety of crisugabalin, an oral calcium channel α2δ-1 subunit ligand, for postherpetic neuralgia.This randomized clinical trial, carried out between November 9, 2021, and January 5, 2023, at 48 tertiary care centers across China had 2 parts. Part 1 was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study consisting of a 2-week screening period, a 7-day run-in period, and a 12-week double-blind treatment period. Part 2 was a 14-week open-label extension study. Investigators, statisticians, trial clinicians, and patients were blinded to trial group assignments. Participants included adults with postherpetic neuralgia with an average daily pain score (ADPS) of at least 4 on the 11-point Numeric Pain Rating Scale over the preceding week, with the exclusion of patients with pain not controlled by prior therapy with pregabalin (≥300 mg/d) or gabapentin (≥1200 mg/d).Patients were randomized 1:1:1 to receive crisugabalin, 20 mg twice daily (ie, 40 mg/d), and crisugabalin, 40 mg twice daily (ie, 80 mg/d), or placebo for 12 weeks. Eligible patients received crisugabalin, 40 mg, twice daily during extension.The primary efficacy end point was the change from baseline in ADPS at week 12.The study enrolled 366 patients (121 patients receiving crisugabalin, 40 mg/d; 121 patients receiving crisugabalin, 80 mg/d; 124 patients receiving placebo; median [IQR] age, 63.0 [56.0-69.0] years; 193 men [52.7%]). At week 12, the least squares mean (SD) change from baseline in ADPS was -2.2 (0.2) for crisugabalin, 40 mg/d, and -2.6 (0.2) for crisugabalin, 80 mg/d, vs -1.1 (0.2) for placebo, with a least squares mean difference of -1.1 (95% CI, -1.6 to -0.7; P < .001) and -1.5 (-95% CI, -2.0 to -1.0; P < .001) vs placebo, respectively. No new safety concerns emerged.Crisugabalin, 40 mg/d, or crisugabalin, 80 mg/d, was well tolerated and demonstrated a statistically significant improvement in ADPS over placebo.ClinicalTrials.gov Identifier: NCT05140863.

基金：
Haisco Pharmaceutical Group Co, Ltd, sponsored and funded the trial, and provided crisugabalin (HSK16149).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 1 区 皮肤病学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 皮肤病学
JCR分区：
出版当年[2022]版：
Q1 DERMATOLOGY
最新[2023]版：
Q1 DERMATOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者：
第一作者机构： [1]Department of Pain Medicine, The First Affiliated Hospital of Nanchang University, Donghu District, Nanchang, Jiangxi, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Zhang Daying,Lei Tiechi,Qin Lanying,et al.Efficacy and Safety of Crisugabalin (HSK16149) in Adults with Postherpetic Neuralgia: A Phase 3 Randomized Clinical Trial[J].JAMA Dermatology.2024,160(11):1182-1191.doi:10.1001/jamadermatol.2024.3410.
APA：
Zhang Daying,Lei Tiechi,Qin Lanying,Li Chenyu,Lin Xuewu...&Lu Qianjin.(2024).Efficacy and Safety of Crisugabalin (HSK16149) in Adults with Postherpetic Neuralgia: A Phase 3 Randomized Clinical Trial.JAMA Dermatology,160,(11)
MLA：
Zhang Daying,et al."Efficacy and Safety of Crisugabalin (HSK16149) in Adults with Postherpetic Neuralgia: A Phase 3 Randomized Clinical Trial".JAMA Dermatology 160..11(2024):1182-1191

资源点击量：25463 今日访问量：0 总访问量：1498 更新日期：2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持：重庆聚合科技有限公司 地址：北京市东城区东交民巷1号(100730)